Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + Polatuzumab Vedotin vs R-GemOx in R/R Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05171647Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab and polatuzumab vedotin in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Roche. Primary endpoints: Objective Response Rate as Determined by the Independent Review Facility in Interim Analysis Population at 23.8 months and Progression-free Survival as Determined by the IRF at 32 months. Started Apr 2022; status: active, not recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05171647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171647.